Prof Jemma C Hopewell (Buffield Department of Population Health, Oxford, UK) discusses Impact of ADCY9 - On response to anacetrapib among 20,000 participants in the HPS3/TIMI55-REVEAL trial.
Filmed on site at ACC 2019 by Radcliffe Cardiology
1. What lead you to research ADCY9 impact?
2. Would you provide an overview of the HPS3/TIMI55-REVEAL trial and the key findings from it?
3. What conculsions should be made and how will this affect future research ?
Videography: Josh Birch
Interviewer: Liam O’Neill
- Acute Coronary Syndromes